|1.||Wallace, Mark S: 11 articles (09/2010 - 01/2004)|
|2.||Fisher, Robert: 6 articles (03/2009 - 01/2004)|
|3.||Webster, Lynn R: 5 articles (07/2015 - 05/2006)|
|4.||Swensen, Andrew M: 5 articles (12/2014 - 04/2008)|
|5.||Rauck, Richard L: 5 articles (09/2010 - 05/2006)|
|6.||Charapata, Steven G: 5 articles (02/2008 - 01/2004)|
|7.||Ellis, David: 5 articles (02/2008 - 06/2003)|
|8.||Deer, Timothy R: 4 articles (05/2013 - 06/2009)|
|9.||McGuire, Dawn: 4 articles (01/2008 - 06/2003)|
|10.||Ver Donck, Ann: 3 articles (06/2014 - 01/2006)|
12/01/2008 - "Ziconotide came to the physicians' table with both doubts and promises; to determine its safety and efficacy, one of the largest and most well-designed randomized double-blind studies in the history of intrathecal therapy was undertaken, and this drug demonstrated efficacy in relieving chronic pain in patients coming from many years of different therapies and therapy failures. "
11/01/2013 - "Across trials, ziconotide recipients had significantly greater reductions in pain intensity during ziconotide treatment than those receiving placebo (primary endpoint). "
07/01/2006 - "In double-blind, placebo-controlled studies, ziconotide significantly improved patient perception of pain from baseline to the end of the study periods, which ranged from 11 to 21 days. "
05/01/2006 - "Slow titration of ziconotide, a nonopioid analgesic, to a low maximum dose resulted in significant improvement in pain and was better tolerated than in two previous controlled trials that used a faster titration to a higher mean dose."
01/01/2006 - "In three pivotal, well designed trials of 5-6 or 21 days' duration, titrated ziconotide was significantly more effective than placebo in treating chronic malignant or nonmalignant pain as assessed by mean percentage improvements from baseline in Visual Analogue Scale Pain Intensity scores. "
10/01/2006 - "Ziconotide, an intrathecal analgesic with orphan drug status, is a novel alternative for the management of chronic intractable pain. "
12/15/2014 - "There is also human validation data from ziconotide, the CaV2.2-selective peptidyl inhibitor used clinically to treat refractory pain. "
12/01/2012 - "Additionally, ziconotide, a selective peptide inhibitor of Ca(V)2.2 channels, is clinically used to treat refractory pain. "
08/01/2010 - "Ziconotide, a state-independent peptide inhibitor of Ca(v)2.2 channels, is efficacious in treating refractory pain but exhibits a narrow therapeutic window and must be administered intrathecally. "
07/01/2009 - "Although ziconotide is approved by the US Food and Drug Administration for monotherapy, it is sometimes used in combination with other intrathecal drugs for the management of intractable pain conditions in clinical practice. "
|3.||Neuralgia (Stump Neuralgia)
09/01/2009 - "Additional studies are needed to establish the long-term efficacy and safety of ziconotide for neuropathic pain."
09/01/2009 - "Evidence from DBPC trials, open-label studies, case series, and case studies suggests that ziconotide, as either monotherapy or in combination with other IT drugs, is a potential therapeutic option for patients with refractory neuropathic pain. "
09/01/2009 - "In the preclinical studies, ziconotide demonstrated antiallodynic effects on neuropathic pain. "
06/01/2012 - "Currently, one drug, Prialt(®), is on the market as a treatment for chronic neuropathic pain. "
09/01/2009 - "The objective of this article is to review the published literature on ziconotide for the treatment of neuropathic pain. "
|4.||Brain Injuries (Brain Injury)
01/01/1994 - "These preliminary results demonstrate that SNX-111 can reduce the injury-induced accumulation of calcium even when administered 1 hour after the insult and offers this compound as a potential therapeutic treatment for traumatic brain injury."
11/01/2000 - "Improvement in mitochondrial dysfunction as a new surrogate efficiency measure for preclinical trials: dose-response and time-window profiles for administration of the calcium channel blocker Ziconotide in experimental brain injury."
07/01/1998 - "Mitochondrial dysfunction after experimental traumatic brain injury: combined efficacy of SNX-111 and U-101033E."
11/01/2000 - "Neurobehavioral protection by the neuronal calcium channel blocker ziconotide in a model of traumatic diffuse brain injury in rats."
01/01/1994 - "The omega-conopeptide, SNX-111 (NEUREX Corporation) was administered to rats 1 hour following a lateral fluid percussion brain injury to determine if the drug could reduced the extent and duration of trauma-induced calcium accumulation. "
09/01/2012 - "Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol."
12/01/2015 - "However, there is a lack of published data regarding the efficacy and safety of intrathecal ziconotide specifically for the treatment of neuropathic cancer pain. "
09/01/2012 - "To determine whether a low starting dosage of ziconotide, followed by slow titration, decreases the incidence of major adverse events associated with ziconotide when used for intractable cancer pain. "
01/01/2011 - "Patients suffering from cancer or non-cancer intractable chronic pain who had been treated with ziconotide IT infusion for at least one month. "
10/01/2008 - "In cancer pain, the available evidence showing that ziconotide is effective after opiate failure is too weak in view of the potential risks. "
|1.||Calcium Channels (Calcium Channel)
|2.||N-Type Calcium Channels (N-Type Calcium Channel)
|3.||Opioid Analgesics (Opioids)
|4.||Morphine (MS Contin)
|7.||Analgesics (Analgesic Drugs)
|10.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)